A RANDOMIZED TRIAL OF THE EFFICACY AND SAFETY OF A STRATEGY OF STARTING WITH NELFINAVIR VERSUS RITONAVIR ADDED TO BACKGROUND ANTIRETROVIRAL (AR) NUCLEOSIDE THERAPY IN HIV-INFECTED INDIVIDUALS WITH CD4+ CELL COUNTS LESS THAN OR EQUAL TO 200/MM3: